To learn more about how your data is used by us when you use the website, please read our Privacy Policy. We use cookies to deliver our services and to ensure that we give you the best experience on our website. For details on our use of cookies, please go to the Cookie Policy

Pseudomonas aeruginosa, a rod-shaped bacterium, is usually found in moist or wet areas such as water and soil. Pseudomonas aeruginosa infection is the most common type of Pseudomonas infections and is caused by strain of bacteria abundantly found in the environment. This bacterial strain usually do not cause harm in healthy people but are ‘opportunistic’ pathogens to cause infection in patients with compromised immune function. Therefore, the main threat is posed to most vulnerable subjects such as hospitalized patients, particularly those in intensive care units, and cancer patients, people with severe burns, and babies in the neonatal units. Pseudomonas aeruginosa is listed as one of the six most dangerous drug-resistant microbes and more than 15% of P. aeruginosa isolates were found resistant to at least three classes of antibiotics which signifies the huge treatment gap present today.

Pseudomonas Aeruginosa Infections can involve several parts of body and the severity and type of illness depends on its entry route and site into the body. Various sites where this infection can cause harm are respiratory tract, blood stream, gastrointestinal tract, urinary tract, cardiovascular system, nervous system, ear, eye, bones and joints, and skin. Pseudomonal infections often become complicated to mange and can be life-threatening. Pseudomonas infections are usually treated with antibiotics. However, antibiotic resistance for these infections is increasing which makes more difficult to treat. The economic burden of healthcare associated infection (HAIs) is very high which have increased the demand for solutions that can be helpful in reducing these infections and the costs associated with them.

Multi-drug resistant (MDR) Pseudomonas poses life threatening danger to patients in critical care. In the U.S. more than 51,000 P. aeruginosa infections occur annually which are associated with healthcare settings such as nursing homes and hospitals. Out of these more than 13% are multidrug-resistant (MDR) phenotype. These multidrug resistance Pseudomonas infections have been highlighted with serious level of threat in a report ‘Antibiotic resistance threats in the United States, 2013’ presented by the Centers for Disease Control and Prevention (CDC). This eventually presents a market opportunity for the companies which can provide solutions in terms of diagnostics, treatment and prevention of Pseudomonas aeruginosa infections. The market for Pseudomonas aeruginosa infections treatment is driven by rate of mortality and lack of drugs which can combat MDR phenotypes of P. aeruginosa. Several pharmaceutical companies are striving to bring innovative drugs into market which can treat Pseudomonas infections.

The large companies such as Roche has been trying to capitalize the unmet market needs through collaboration and licensing agreements. For instance, Roche entered into an exclusive worldwide agreement with Polyphor Ltd., to develop and commercialize latter company’s investigational antibiotic, POL7080. The companies in the market have historically focused in the United States and Europe. However, with the increasing competition in these geographies, the larger players are encouraged to engage in untapped markets in Asia and Latin America.

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.